[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-behaviors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-behaviors":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,43,73,94,124,150,192,222,248,271,293,316,341,362,403,429,453,472,490,507,525,561,593,621,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054115","switch-or-quit-r01-100054115",false,"NCT06373679","Switch or Quit R01","Non-cigarette Tobacco Products as Harm Reduction Tools in Smokers Who Failed to Quit With Traditional Methods","Inclusion Criteria\n\n* Adults 21+ who previously had a quit attempt using FDA-approved pharmacotherapy.\n* Interest in reducing harms from tobacco use or quitting smoking\n\nExclusion Criteria\n\n* Pregnant, breastfeeding, or trying to become pregnant.\n* Household member currently enrolled in the study\n* Planning to move out of the area within the next 7 months",true,"ALL","21 Years",{"count":21,"type":22},225,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates whether non-cigarette tobacco products (e-cigarettes) can help smokers quit smoking as compared to traditional quit methods (nicotine replacement therapy or varenicline\u002FChantix). Participants in this study will be randomly assigned to one of two groups, then will have a choice between the offered products of that group. Participants in the e-cigarette group will have a choice of e-cigarette brand and flavor. Participants in the medication group will have choice between nicotine replacement therapy (patches and lozenges) or varenicline, also known as Chantix. Participation will last 6 months and will include weekly phone calls for the initial 7-weeks plus a 11-week phone call and a 6-month follow-up visit. Participants will also complete electronic daily diaries during the first 7-weeks.",[28,29],"Cigarette Smoking","Smoking Behaviors","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2024-07-10",{"date":38,"type":22},"2027-05-01",{"name":40,"class":41},"Medical University of South Carolina","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100644677","omega-3-plus-low-dose-aspirin-in-smokers-with-stage-iii-periodontitis-100644677","NCT07673185","Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis","Clinical and Biochemical Evaluation of the Effect of Omega-3 Fatty Acids Plus Low-Dose Aspirin as an Adjunct to Non-Surgical Periodontal Therapy in Smoker Patients With Stage III Periodontitis: A Randomized Double-Blind Placebo-Controlled Clinical Trial","OASP","Inclusion Criteria:\n\n* \\- Male or female smokers aged 30 to 50 years.\n* Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.\n* Probing pocket depth (PPD) ≥ 5 mm.\n* Clinical attachment loss (CAL) ≥ 5 mm.\n* Presence of at least 20 natural teeth.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* \\- Systemic diseases affecting periodontal health.\n* Pregnancy or lactation.\n* Periodontal treatment within the previous 6 months.\n* Use of antibiotics or anti-inflammatory drugs within the previous 6 months.\n* Allergy or hypersensitivity to omega-3 fatty acids or aspirin.\n* Long-term anticoagulant therapy.\n* History of gastric ulcer or bleeding disorders.\n* Participation in another clinical trial within the previous 3 month","30 Years","50 Years",{"count":54,"type":22},40,[25],"This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment",[58,59,29],"Periodontal Disease","Periodontitis (Stage 3)",[61,62,63],"omega 3","smoker","stage 3","2026-06-23",{"date":66,"type":34},"2026-06-29",{"date":68,"type":34},"2025-01-15",{"date":70,"type":22},"2026-10-30",{"name":72,"class":41},"Al-Azhar University",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":42},"100600791","influence-of-authorized-smokeless-tobacco-product-modified-risk-claims-i-consumer-product-demand-100600791","NCT07102082","Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand","Ifluence of Authorized Smokeless Tobacco Product Modified Risk Claims II: Laboratory Assessment of Sensory and Subjective Effect","Inclusion Criteria:\n\n* Residing in one of the 8 counties of Western New York (Erie, Niagara, Cattaraugus, Chautauqua, Allegheny, Livingston, Genesee, Orleans, Wyoming).\n* Smoke cigarettes every day, at least 5 cigarettes per day, for at least 1 year.\n* Open to trying a non-combusted oral tobacco product.\n* Have access to a device (ie: computer\u002Ftablet\u002Fsmartphone) with internet capabilities to participate in an online survey study.\n* Have the ability to read, write, and communicate in English.\n* Participant must understand the investigational nature of this study and an Independent Ethics Committee\u002FInstitutional Review Board approved information sheet prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Plan to quit smoking in the next 30 days.\n* Use of smokeless tobacco at least weekly in the last 6 months.\n* Lifetime use (that is, ever used at any time prior to the study) of Copenhagen or General Snus.\n* Unwilling or unable to follow protocol requirements.\n* Pregnant or planning to become pregnant (by self report)",{"count":81,"type":22},160,[25],"To explore consumer responses to the announcement and implementation of new modified risk claims for Copenhagen and General Snus (brands of smokeless tobacco (ST) products) using a series of complementary and innovative research activities and methods.",[29],"2026-05-28",{"date":87,"type":34},"2026-06-01",{"date":89,"type":34},"2025-09-25",{"date":91,"type":22},"2027-09-30",{"name":93,"class":41},"Roswell Park Cancer Institute",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100641102","phase-2-multi-site-trial-of-tirzepatide-for-smoking-cessation-100641102","NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation","A Multi-Site Trial of Tirzepatide for Smoking Cessation","Inclusion Criteria:\n\n1. Age 21-65 years\n2. Body mass index ≥ 25kg\u002Fm2 at the baseline screening\n3. Reporting ≥10 cigarettes per day, on average, for the past 6 months and \\> 2 year duration of smoking\n4. Interest in making a long-term cessation attempt within the next 30-60 days\n5. Willingness to receive study medication and standard-of-care smoking cessation supports (nicotine replacement therapy and a smoking cessation app)\n6. Ability to adhere to weekly visits and study procedures over the study period (i.e., no plans to move or travel for extended periods)\n7. Exhaled CO of \\>5ppm at baseline\n8. Use of an acceptable birth control method for female participants\\*\n9. Ability to read and communicate in English\n\nExclusion Criteria:\n\n1. BMI \\\u003C 25 kg\u002Fm2 at screening\n2. History of diabetes, diabetes-attributable medical conditions, or HbA1c ≥6.5% at baseline\n3. Recent (past 90 days) active suicidal ideation or lifetime history of suicide attempt\n4. Current treatment for psychotic disorders or mood disorders with psychotic features (e.g., schizophrenia, schizoaffective disorder, depression with psychotic features), current treatment for bipolar disorder (with or without psychotic features), or current secondary psychosis due to substance use or another medical condition\n5. Meeting DSM-5 criteria for a current (past 12 months) substance use disorder other than tobacco use disorder, mild or moderate cannabis use disorder, or mild or moderate alcohol use disorder.\n6. Recent (past 30 day) self-report of illicit drug use (excluding cannabis) or non-prescribed opioids; or positive urine screen for illicit drugs. A positive screen for opioids will be allowed if the participant is prescribed an opioid replacement therapy medication and can provide documentation.\n7. Past 30-day initiation of psychiatric medications (e.g., SSRIs) or changes to medication dose\n8. Treatment with tirzepatide or another GLP-1RA medication in the prior 6 months\n9. Current (past month) treatment with other weight loss, diabetes, or smoking cessation medications (varenicline or bupropion; excluding nicotine replacement products)\n10. Severe GI disease (e.g., gastroparesis, ulcerative colitis).\n11. History of gastric bypass surgery or other surgeries of the stomach\n12. Any health condition or treatment\u002Fmedication that would preclude the use of tirzepatide or NRT, in the opinion of the study physician, including severe cardiovascular disease\n13. History of chronic pancreatitis or acute pancreatitis in the last 6 months\n14. Currently nursing, pregnant, or anticipating pregnancy\n15. History of diabetic retinopathy, proliferative retinopathy, or maculopathy\n16. Elevated serum lipase, amylase, bilirubin, or ALP, ALT, or AST (\\>5x upper limit of normal range)\n17. History of malignant neoplasms in the last 5 years, except non-melanoma skin cancer\n18. Inability to attend weekly clinic visits as scheduled (i.e., based on travel or work schedule)\n19. Currently enrolled in another clinical study involving an investigational product\n20. Currently living in the same household as someone taking a GLP-1 medication, or living with a current or former participant in the present trial\n21. Planned surgical procedures requiring anesthesia during the planned study medication period\n22. Personal or family history of medullary thyroid cancer\n23. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2)\n24. Treatment with other weight loss (e.g., phentermine), or FDA-approved, non-NRT smoking cessation therapies (varenicline, bupropion) or FDA-approved AUD medications (naltrexone, acamprosate, disulfiram) or off-label AUD medications (e.g., topiramate) in the past 90 days\n25. Any health condition or treatment\u002Fmedication that would preclude use of tirzepatide or NRT, in the opinion of the site physicians including thyroid enlargement.","65 Years",{"count":103,"type":22},300,[105],"PHASE2","This multi-site clinical trial will generate data on the efficacy of tirzepatide for smoking cessation and associated outcomes (e.g., post-cessation weight gain) in treatment-seeking people who smoke (PWS) with overweight or obesity. A sample of 300 treatment-seeking people who smoke with body mass index of 25 kg\u002Fm2 or greater will be recruited from four geographic sites (University of Southern California, Yale University, University of Chicago, and University of Colorado Anschutz Medical Campus) to participate in a parallel-arm, dose-escalating, placebo-controlled trial. Participants will attend weekly clinic visits to receive subcutaneous tirzepatide or placebo over 16 weeks (Visit Weeks 1-16), followed by follow-up visits at Week 17 and Week 27. Medication will be prescribed according to the standard dose titration schedule for the first 16 weeks of treatment (initial dose: 2.5mg\u002Fweek; final dose: 10mg\u002Fweek). All participants will also receive nicotine patches.",[108,29],"Smoking Cessation",[110,111,112,113],"Addiction","GLP-1","Tirzepatide","Substance Use Disorder","2026-05-18",{"date":116,"type":34},"2026-05-22",{"date":118,"type":22},"2026-05-31",{"date":120,"type":22},"2028-09",{"name":122,"class":41},"University of Southern California",4,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100639243","abuse-liability-of-two-modern-oral-nicotine-pouched-products-100639243","NCT07595055","Abuse Liability of Two Modern Oral Nicotine Pouched Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability of Two Modern Oral Nicotine Pouched Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n6. Reports daily use of ST products (i.e., moist snuff) and agrees to use the same UB ST throughout the study period. The UB moist snuff is defined as the reported moist snuff brand and style currently used most frequently by the participant.\n7. Expired breath carbon monoxide (eCO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day 1).\n8. Positive urine cotinine test (i.e., ≥200 ng\u002FmL) via dipstick at Screening and at Check-in Day 1.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991) OR response at Screening to \"How soon after you wake up do you place your first dip?\" is either \"Within 5 minutes\" or \"6-30 minutes\" from the Fagerström Test for Nicotine Dependance-Smokeless Tobacco (FTND-ST) (Ebbert et al., 2006).\n10. Willing to use Study IPs, their UB cigarette and UB moist snuff (Study IP Product S) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. abstinence;\n    4. non-hormone releasing intrauterine devices (IUD);\n    5. vasectomized partner; or\n    6. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n14. BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening)\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day 1.\n10. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n11. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n12. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n13. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n14. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within 30 days prior to signing the informed consent.\n15. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n16. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n17. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n18. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day 1.\n19. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day 1.\n20. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n21. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n22. Drinks more than 21 servings of alcoholic beverages per week.\n23. Determined by an investigator to be inappropriate for this study.","60 Years",{"count":54,"type":22},[25],"This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.",[136,29,137,138],"Smoking","Tobacco Use","Tobacco Smoking","NOT_YET_RECRUITING","2026-05-12",{"date":142,"type":34},"2026-05-19",{"date":144,"type":22},"2026-06-15",{"date":146,"type":22},"2026-11-30",{"name":148,"class":149},"RAI Services Company","INDUSTRY",{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":171,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100638763","smoking-cessation-with-wearables-to-improve-general-oral-health-and-quality-of-life-100638763","NCT07593742","Smoking Cessation With Wearables to Improve General, Oral Health and Quality of Life","Smoking Cessation Programme in Telerehabilitation Assisted by Telemonitoring With Non-Invasive Wearable Devices for the Improvement of Oral Health, General Health and Quality of Life","Wear-Smile","Inclusion Criteria:\n\n* Subjects who smoke ≥ 5 cigarettes per day (traditional or equivalent in nicotine content in non-combustible tobacco or liquid\u002Fvape), regardless of the severity of nicotine dependence\n* Subjects ≥ 18 years of age\n* Ability and willingness to provide informed consent or presence of a legal representative who consents\n* Subjects in possession of home medical devices for measuring cardiopulmonary parameters (sphygmomanometer and pulse oximeter) (requirement applicable to participants assigned to the control group)\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnant or breastfeeding women\n* Subjects with a remote or current history of using smoking cessation methods\n* Subjects with acute dependence on alcohol or other substances of abuse other than nicotine\n* Pathologies with advanced neurocognitive degeneration\n* Unstable psychiatric conditions (subjects with active suicidal ideation, hospitalization for psychiatric reasons and\u002For changes in psychiatric medication for less than 3 months)\n* Inability or refusal to sign informed consent\n* Inability to access the integrated telemedicine platform and\u002For wearable remote monitoring devices (requirement applicable to participants assigned to the experimental group)","18 Years",{"count":160,"type":22},102,[25],"Tobacco smoking remains one of the leading preventable causes of disease, disability, and premature death worldwide. According to the World Health Organization, tobacco use is responsible for more than eight million deaths each year globally, including deaths caused by direct smoking and exposure to secondhand smoke. Smoking is a major risk factor for a wide range of chronic diseases, including cardiovascular diseases, chronic respiratory diseases, several types of cancer, and numerous oral health conditions. In addition to systemic effects, tobacco use is strongly associated with oral potentially malignant disorders and oral squamous cell carcinoma, representing a significant burden for public health systems.\n\nDespite the well-documented health risks, smoking cessation remains difficult for many individuals due to the addictive properties of nicotine and the complex behavioral and psychological components associated with tobacco dependence. Multimodal smoking cessation programs that combine behavioral counseling, psychological support, and continuous monitoring have been shown to increase the likelihood of successful cessation. However, access to these programs may be limited by logistical barriers, including geographic distance, time constraints, and limited availability of specialized services.\n\nIn recent years, telemedicine and digital health technologies have emerged as promising tools to support healthcare delivery and improve access to treatment programs. Telemedicine platforms allow remote interaction between patients and healthcare professionals, facilitating communication, follow-up, and monitoring of patients over time. Additionally, wearable devices and remote monitoring systems enable the collection of physiological and behavioral data outside traditional clinical settings, providing clinicians with valuable information to support personalized interventions.\n\nThe aim of this study is to evaluate the effectiveness and feasibility of a smoking cessation program delivered through a telerehabilitation model supported by an integrated telemedicine platform and wearable remote monitoring devices. The program is designed to support individuals who smoke tobacco products, including both combustible tobacco and alternative nicotine-containing products, by providing behavioral and psychological interventions combined with continuous remote monitoring.\n\nParticipants enrolled in the study will be assigned to one of two groups. The intervention group will participate in a telerehabilitation program delivered through a dedicated telemedicine platform. This program will include structured behavioral and psychological treatment sessions aimed at supporting smoking cessation, along with remote monitoring through non-invasive wearable devices that allow healthcare professionals to track selected physiological parameters and patient engagement during the treatment process.\n\nThe control group will receive the same multimodal behavioral and psychological treatment program but delivered through conventional rehabilitation methods without the use of telemedicine technologies or wearable monitoring devices.\n\nBy comparing these two approaches, the study aims to explore whether the integration of telemedicine and wearable technologies into smoking cessation programs may improve patient engagement, facilitate monitoring, and potentially enhance the effectiveness of behavioral interventions aimed at reducing tobacco use. The findings of this study may contribute to the development of innovative digital health strategies for smoking cessation and provide evidence to support the integration of telemedicine into addiction treatment and preventive healthcare programs.",[164,165,29,108,166,167,168,169,170],"Smoking ( Cigarette)","Smoking (Tobacco) Addiction","Smoking Dependence","Smoking Addiction","Smoking Cessation Intervention","Smoking E-cigarette","Smoking Abstinence",[136,172,173,174,175,176,177,178,179,180,181,182,183,184],"Smoking cessation","Smoking addiction","Tobacco","Wearable device","Telerehabilitation","Oral Health","Periodontal Health","General Health","Quality of life","Periodontal disease","E-cigarette","Heat not burn tobacco","Smoking abstinence","2026-05-11",{"date":114,"type":34},{"date":87,"type":22},{"date":189,"type":22},"2027-11-01",{"name":191,"class":41},"University of Salerno",{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":42},"100585332","therapeutic-contact-intensity-in-a-psychological-smoking-cessation-intervention-with-an-app-100585332","NCT06900985","Therapeutic Contact Intensity in a Psychological Smoking Cessation Intervention With an App","Assessment of a Psychological Treatment for Smoking Cessation Combined With an App According to the Intensity of Therapeutic Contact: Randomized Controlled Trial","TREATINTSMOKE","Inclusion Criteria:\n\n* aged 18 or over\n* wishing to participate in the treatment\n* providing written informed consent\n* smoking at least 5 cigarettes per day\n* completion of all pre-treatment assessment questionnaires\n* having a valid email address\n* having an Android or iOS smartphone and being willing to use it throughout the treatment\n\nExclusion Criteria:\n\n* a diagnosis of severe mental disorder (bipolar disorder and\u002For psychotic disorder)\n* concurrent substance use disorder (alcohol, cannabis, stimulant, hallucinogen and\u002For opioid)\n* using other tobacco products (electronic cigarette with nicotine, cigars or cigarillos)\n* having completed an effective psychological treatment to quit smoking during the previous year\n* having completed a pharmacological treatment to quit smoking in the last year (any smoking cessation medication approved by the Agencia Española del Medicamento)\n* having a physical pathology involving high vital risk that requires immediate intervention (e.g., recent myocardial infarction)\n* having visual difficulties that prevent the use of the App.",{"count":201,"type":22},429,[25],"This randomized controlled trial intends to examine the efficacy of a smoking cessation intervention with an App according to the intensity of therapeutic contact. Participants will be assigned to one of three groups. The first group will receive eight sessions with trained psychologists alongside access to the App. The second group will receive four sessions with trained psychologists plus App access. The control group will only have access to the App. This study seeks to determine the impact of different levels of therapeutic contact on abstinence outcomes.",[29],[206,207,208,209,210,211,212],"smoking","treatment","cognitive-behavioral","therapeutic-contact intensity","digital intervention","eHealth","randomized controlled trial","2026-04-27",{"date":215,"type":34},"2026-04-28",{"date":217,"type":22},"2026-09",{"date":219,"type":22},"2028-04",{"name":221,"class":41},"University of Santiago de Compostela",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":42},"100628283","evaluation-of-a-novel-mhealth-intervention-for-people-who-are-ambivalent-about-quitting-smoking-100628283","NCT07459621","Evaluation of a Novel mHealth Intervention for People Who Are Ambivalent About Quitting Smoking","Evaluation of a Novel mHealth Intervention for People Who Are Ambivalent About Quitting Smoking: A Randomized Controlled Trial","GEMS","Inclusion Criteria:\n\n* 18 years of age and older\n* Current cigarette smoker who is ambivalent about smoking\n* Not actively using any treatment to quit smoking\n* Own and regularly use a smartphone\n* State willingness to install and use their assigned app\n* Willingness to receive study communications\n* Smoke at least half a pack a day\n* Meet geolocation requirements\n\nExclusion Criteria:\n\n* A lifetime history of dementia or psychosis\n* Visual impairments that prevent viewing phone content and they lack adaptive devices\n* Report medical contra-indications for over-the-counter NRT use\n* Due to the potential for bias introduced by fraudulent participants, other exclusions will be applied to deter fraudulent enrollment.",{"count":231,"type":22},800,[25],"The goal of this study is to compare the effectiveness of two smoking cessation programs to determine which better helps people change their smoking behavior, the control or the experimental intervention? Both interventions include access to a mHealth app and other publicly available stop-smoking resources. The two app versions each include best practice advice and guidance for quitting smoking, but one includes additional content designed for people who aren't ready to quit smoking.\n\nThe investigators hypothesize that people who receive the experimental intervention will be more likely to request additional stop-smoking resources offered through the intervention and report smoking abstinence after 6 months.\n\nThe investigators also hypothesize people assigned to the experimental app will have better app engagement and be more likely to report positive changes in their smoking behavior and use of other evidence-based stop smoking treatments that are publicly available.",[29],[136,236,237,238],"mHealth","motivation","ambivalent smokers","2026-04-24",{"date":241,"type":34},"2026-04-30",{"date":243,"type":34},"2026-03-29",{"date":245,"type":22},"2028-12",{"name":247,"class":41},"Kaiser Permanente",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":42},"100439310","smoke-free-safecare-establishing-a-smoke-free-home-in-cps-involved-families-100439310","NCT05000632","Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families","Establishing Smoke-free Homes With Families Involved in Child Protective Services: Effectiveness-implementation Trial of an Integrated Program","SFSC","Provider Inclusion Criteria:\n\n* SafeCare providers in this study must 1) have completed the SafeCare workshop and passed field Certification (9 sessions of SafeCare delivered with fidelity according to the SafeCare Fidelity Checklist); 2) be employed at an accredited SafeCare agency in a target state based on Centers for Disease Control and Prevention (CDC) adult smoking data or prior SafeCare research documenting high smoking rates.\n\nCaregiver Inclusion Criteria:\n\n* Caregivers in this study must meet the following inclusion criteria to participate: 1) Referred to a SafeCare Provider study participant; 2) Reports in-home smoking behavior by herself or another person (person must reside in the home 3 or more nights a week) 3) Caregiver must be aged 18 or older and 4) Mother must be a parent to a child between the ages of 0 and 5 (or 0 - 9 if in the state of Oklahoma).\n\nProvider Exclusion Criteria:\n\n* SafeCare providers will be excluded if they have planned for significant employment leave, resignation, or promotion during the study period.\n\nCaregiver Exclusion Criteria:\n\n* We will exclude those who 1) Report that no one smokes in the home; 2) Demonstrate an inability to understand their responsibilities as outlined in the consent form. This will be determined as the research staff verbally go through the consent form with the mothers. If mothers do not understand the consent form and subsequent procedures, they will be excluded.","89 Years",{"count":258,"type":22},268,[25],"Smoke Free SafeCare (SFSC) is a proposed braided intervention consisting of two evidence-based interventions: Some Things are Better Outside (STBO), aimed at promoting smoke free home rules, and SafeCare, aimed at reducing child maltreatment and improving mother and child outcomes. STBO is effective in creating smoke free homes and reducing second-hand smoke in low-SES (socioeconomic status) households. SafeCare is an effective parent training program that is broadly disseminated in child protective services in the United States. SafeCare is a promising mechanism to effectively increase the reach of STBO to reduce SHS (secondhand smoke) exposure in families with documented high rates of tobacco use and children with cumulative risk for negative health outcomes.",[262,29],"Child Maltreatment","2026-04-21",{"date":239,"type":34},{"date":266,"type":34},"2022-04-19",{"date":268,"type":22},"2026-12",{"name":270,"class":41},"Georgia State University",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":42},"100522026","effects-of-e-cigs-vs-pouches-on-cigarette-smoking-and-addiction-100522026","NCT06077240","Effects of E-cigs vs Pouches on Cigarette Smoking and Addiction","Evaluating The Effects Of E-cigarettes Versus Oral Nicotine Pouches and Product Constituents (Menthol Flavor, Nicotine Concentration) On Adult Cigarette Smoking and Addiction","Inclusion Criteria:\n\n* 21+ years old\n* English literate\n* Currently smoking cigarettes, biochemically confirmed\n\nExclusion Criteria:\n\n* Currently using smoking cessation pharmacotherapies (NRT, bupropion, varenicline)\n* Currently pregnant or breastfeeding\n* Significant current medical or psychiatric condition\n* Known hypersensitivity to propylene glycol",{"count":279,"type":22},256,[25],"The study will recruit an anticipated 256 adults who currently smoke cigarettes and report a willingness to try switching to alternative, non-combustible products. Participants will be randomized to receive either e-cigarettes or nicotine pouches for a duration of 4 weeks and to 1 of 4 possible regulatory scenarios within products where flavor availability is either menthol and tobacco\u002Funflavored available or tobacco\u002Funflavored only available, and nicotine concentration is either higher (5% e-cig, 6mg pouch) or lower (2.4% e-cig, 3mg pouch). Participants will return for bi-weekly research visits (in person or remote videocall) to complete measures for study aims. Participants will complete a final follow-up at Week 6 to assess maintenance of cigarette reduction and willingness to continue using products once they are no longer provided. The investigators expect to observe which products and constituents lead to greater smoking reduction.",[136,29,283],"Nicotine Dependence","2026-03-17",{"date":286,"type":34},"2026-03-19",{"date":288,"type":34},"2024-08-20",{"date":290,"type":22},"2028-04-01",{"name":292,"class":41},"Yale University",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":17,"sex":18,"minAge":300,"maxAge":101,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":315},"100629551","phase-1-nordic-spirit-pouch-nicotine-pharmacokinetics-abuse-liability-100629551","NCT07476144","Nordic Spirit Pouch Nicotine Pharmacokinetics Abuse Liability","Nicotine Pharmacokinetics and Subjective Effects of 9 Nordic Spirit Nicotine Pouch Products in Adult Cigarette Smokers: A Controlled, Randomized, Cross-over Study With a Balanced Incomplete Block Design.","Inclusion Criteria:\n\n1. Voluntary consent to participate in this study documented on the signed ICF.\n2. Healthy adult males and females ≥22 and ≤65 years of age, at screening.\n3. Smokers and smokers that use other tobacco products (i.e., snus, moist snuff, Electronic Nicotine Delivery Systems, NP) will be considered. Smoking history (self-reported at screening) of an average of at least 5 but no more than 30 factory-manufactured combustible cigarettes daily for at least 12 months prior to screening. Brief periods (i.e., up to 7 consecutive days) of nonsmoking during the 3 months prior to screening (e.g., due to illness or participation in a study where smoking was prohibited) will be permitted.\n4. Participants must demonstrate the ability to use a 12-mg NP for 30 minutes.\n5. Participants who use THC, must be willing to abstain from THC use for 7 days before Check-in and able to participate in the study without THC use.\n6. Participants must be generally healthy, free of lifetime malignant tumors, and without clinically significant abnormalities as assessed by the Investigator based on the review of medical and surgical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluations conducted at screening and Check-in, as applicable. A single repeat measurement\u002Ftest may be performed to confirm vital signs, 12-lead ECG, and clinical laboratory tests abnormalities (i.e.,to confirm that a participant is eligible).\n7. Screening and first Check-in blood pressure ≤150\u002F90 mmHg measured after being in the supine position or in the most recumbent position possible for at least 5 minutes. Two rechecks may be performed at the Principal Investigator's discretion.\n8. Positive urine cotinine (≥200 ng\u002FmL) at screening.\n9. Exhaled carbon monoxide ≥8 ppm at screening.\n10. Male participants, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from first Check-in (Day -1) to the clinical site until 90 days after the last administration of study product. Adequate contraception for the male participant (and his female partner, if she is of childbearing potential) is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence from heterosexual intercourse, in accordance with the lifestyle of the subject, is also acceptable.\n11. Negative pregnancy test at screening and first Check-in (Day -1) for all female participants.\n12. Female participants who are heterosexually active and of childbearing potential (e.g., neither surgically sterile at least 6 months prior to first Check-in nor postmenopausal with amenorrhea for at least 12 months prior to first Check-in with FSH levels consistent with postmenopausal status) must have been using one of the following forms of contraception for the time period indicated and agree to continue using it through completion of the study:\n\n    * Hormonal (e.g., oral, vaginal ring, transdermal patch, implant, injection) consistently for at least 3 months prior to first Check-in, when used in combination with male condoms with spermicide (use of NuvaRing is at the Principal Investigator's discretion)\n    * Double barrier (e.g., condom with spermicide or diaphragm with spermicide) consistently for at least 2 weeks prior to first Check-in\n    * Intrauterine device or system (utilize Principal Investigator discretion regarding use of hormonal or nonhormonal devices) for at least 3 months prior to first Check-in\n    * Exclusive partner who is clinically sterile (i.e., documented infertility or surgical sterilization; see below for additional information on sterility) or has been vasectomized for at least 6 months (inclusive) prior to first Check-in\n    * Note: Sexual abstinence, defined as refraining from intercourse, is allowed when this is in line with the preferred and usual lifestyle of the participant. Female participants of childbearing potential who are not currently engaging in heterosexual intercourse must agree to use one of the above methods of birth control through completion of study, in the event that they have heterosexual intercourse during the course of the study.\n13. Female participants who are of nonchildbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to first Check-in:\n\n    * Hysteroscopic sterilization (including Essure or similar nonsurgical sterilization procedures)\n    * Bilateral tubal ligation or bilateral salpingectomy\n    * Hysterectomy\n    * Bilateral oophorectomy\n    * Or be postmenopausal with amenorrhea for at least 12 months prior to first Check-in and have FSH levels consistent with postmenopausal status.\n14. Able to communicate effectively with the study personnel and willing to comply with the requirements of the study.\n15. Willing and able to use all of the study products in-confinement and product use sessions\n\nExclusion Criteria:\n\n1. Self-reported puffers (i.e., adult smokers who draw smoke from the cigarette into the mouth and throat but do not inhale).\n2. Any postponement of a quit attempt to participate in the study; or any attempts to quit smoking in the 3 months prior to Check-in).\n3. Poor dentition that prevents participant from using nicotine gum.\n4. History or presence of any type of malignant tumor or clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary, immunologic, psychiatric, or cardiovascular disease, or any other condition that, in the opinion of the Investigator, would interfere with the absorption, distribution, metabolism, or excretion of nicotine or jeopardize the safety of the participant or impact the validity of the study results.\n5. Current evidence or any history of congestive heart failure.\n6. Any other condition or prior therapy that, in the Investigator's opinion, would make the participant unsuitable for the study, or unable or unwilling to comply with the study procedures.\n7. All prescribed medication must have been stopped at least 14 days prior to (first) admission to the clinical site. An exception is made for hormonal contraceptives that may be used throughout the study.\n8. All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's wort) must have been stopped at least 14 days prior to (first) admission to the clinical site. An exception is made for acetaminophen that is allowed up to admission to the clinical site.\n9. Clinically significant abnormal vital sign, physical examination (including oral cavity and oropharynx), medical history, or clinical laboratory finding(s), in the opinion of the Investigator.\n10. Positive test for HIV-1 or HIV-2; or HBsAg or HCV consistent with current infection at screening.\n11. Diabetes mellitus that is not controlled by diet\u002Fexercise alone, in the opinion of the Investigator. Fasting plasma glucose \\>126 mg\u002FdL (7 mmol\u002FL) is exclusionary. One recheck may be performed for fasting plasma glucose values \\>126 mg\u002FdL but \\\u003C200 mg\u002FdL.\n12. An acute illness (e.g., upper respiratory infection, viral infection) requiring treatment with prescribed medicines within 2 weeks prior to Check-in.\n13. History of surgery or major trauma within 12 weeks of screening, or surgery planned during the study through EOS.\n14. History of alcohol abuse or drug abuse within 24 months prior to Check-in.\n15. Consumption of alcohol-containing food or beverages within 48 hours prior to Check-in.\n16. Positive screen for alcohol (breath or urine) or drugs of abuse (urine), regardless of the reason of use at screening or Check-in, with the exception of positive results for THC. If positive for THC at check-in (Day -1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of the Investigator.\n17. Fever (i.e., body temperature \\>100.5°F) at screening or Check-in; 1 recheck may be performed at the Investigator's discretion.\n18. BMI \\\u003C18.0 kg\u002Fm2 or \\>40.0 kg\u002Fm2 at screening.\n19. Estimated glomerular filtration rate \\\u003C80 mL\u002Fminute using the CKD-EPI formula (Medscape) at screening.\n20. Serum alanine aminotransferase ≥1.5 times the upper limit of normal and\u002For aspartate aminotransferase ≥2.0 times the upper limit of normal at screening; 1 recheck may be performed at the Investigator's discretion.\n21. Female participants who are pregnant (positive pregnancy test at screening or Check-in), lactating, or intend to become pregnant from screening through EOS.\n22. Use of prescription or OTC bronchodilator medication (e.g., inhaled or oral β-agonists) for treatment of any illness within 12 months prior to Check-in.\n23. Use of antibiotics within 2 weeks prior to Check-in.\n24. Use of medications known or suspected to interact with cytochrome P450 2A6 (including, but not limited to, amiodarone, amlodipine, amobarbital, buprenorphine, clofibrate, clotrimazole, desipramine, disulfiram, entacapone, fenofibrate, isoniazid, ketoconazole, letrozole, methimazole, methoxsalen, metyrapone, miconazole, modafinil, orphenadrine, pentobarbital, phenobarbital, pilocarpine, primidone, propoxyphene, quinidine, rifampicin, rifampin, secobarbital, selegiline, sulconazole, and tioconazole, tranylcypromine) within 14 days or 5 half lives of the medication, whichever is longer, prior to Check-in.\n25. Has taken other investigational drugs\u002Fproducts or participated in any clinical study for an investigational drug, device, biologic, or for a tobacco product within 30 days or 5 half-lives (if known) of the investigational product's PK, PD, or biological activity (if known), whichever is longer, prior to first administration of study product in this study or is currently participating in another clinical study prior to Check-in.\n26. Has received a vaccination within 14 days prior to Check-in.\n27. Plasma donation within 7 days prior to Day 1.\n28. Donation of ≥1 unit of blood or blood products (with the exception of plasma as noted), had significant blood loss \\>450 mL, or received whole blood or a blood product transfusion within 56 days prior to Check-in.\n29. Strenuous activity (as assessed by the Investigator) within 48 hours prior to Check-in.\n30. Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current or former employee of the tobacco industry, or a named party or class representative in litigation with any tobacco company.\n31. Participant or a first-degree relative (i.e., parent, sibling, child, spouse) is a current employee of the study site or service provider.\n32. Unwilling or unlikely to comply with the requirements of the study","22 Years",{"count":302,"type":22},55,[304],"PHASE1","Nicotine pharmacokinetics and subjective effects of 9 Nordic Spirit Nicotine Pouch Products in adult cigarette smokers: A controlled, randomized, cross-over study with a balanced incomplete block design.",[29],"2026-03-11",{"date":284,"type":34},{"date":310,"type":34},"2026-01-08",{"date":312,"type":22},"2026-10",{"name":314,"class":149},"JT International SA",2,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":331,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":315},"100588724","act-lung-health-intervention-phase-two-100588724","NCT06945120","ACT Lung Health Intervention: Phase Two","Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans","Inclusion Criteria:\n\n* Self-identify as either Chinese or Korean\n* Speak either Korean, Mandarin, or English\n* Are 18 years of age or older\n* Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days)\n* Will live in the United States for the next 12 months\n\nExclusion Criteria:\n\n* Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months.\n* We will not include any of the following special populations:\n\n  * Adults unable to consent.\n  * Adults younger than 50 or older than 80 years\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners","100 Years",{"count":325,"type":22},50,[25],"This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.",[108,29,329,330,165],"Smoking, Tobacco","Smoking, Cigarette",[108,332,165,330,329,29],"Lung Cancer Screening",{"date":334,"type":34},"2026-03-13",{"date":336,"type":34},"2025-11-04",{"date":338,"type":22},"2026-12-31",{"name":340,"class":41},"Dana-Farber Cancer Institute",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":42},"100525189","a-clinical-trial-of-adaptive-treatment-for-early-smoking-cessation-relapse-100525189","NCT06118502","A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse","ADAPT","Inclusion Criteria:\n\n* Smokers who want to quit\n\nExclusion Criteria:\n\n* Non-smokers",{"count":349,"type":22},544,[25],"This is a research study to find out if treatment decision making can be improved for smokers who find it difficult to quit with medications. Everyone who participates in this study will receive free product, either nicotine replacement therapies (patches and lozenges), varenicline, or a harm reduction product (e-cigarette) for a full 12 weeks. Most participants will receive some combination of these treatments, depending on individual response to each.\n\nAll visits and study assessments will be entirely remote. All treatments will be provided free of charge for the first 12 weeks. After that, the study team will contact the participants 6 months after the first study phone call to complete another survey. The study lasts six months and will involve 8 surveys.",[28,29,353],"Treatment","2026-03-04",{"date":356,"type":34},"2026-03-06",{"date":358,"type":34},"2024-03-25",{"date":360,"type":22},"2028-03-31",{"name":40,"class":41},{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":17,"sex":18,"minAge":370,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":386,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":42},"100617156","impact-of-lifestyle-on-health-maintenance-a-randomized-controlled-trial-100617156","NCT07314957","Impact of Lifestyle on Health Maintenance: A Randomized Controlled Trial","The Role of Lifestyle in Maintaining Health: Biological, Psychological and Social Responses of the Organism to Lifestyle","LifeHealth-RCT","Inclusion Criteria:\n\n* adults aged 20 years and older\n* overweight or obesity (BMI ≥25 kg\u002Fm²),\n* stable body weight over the past 6 months\n* physically inactive.\n\nExclusion Criteria:\n\n* HbA1c \\>12%\n* insulin therapy\n* severe psychiatry and severe chronic illnesses of parents\n* diseases of the hypothalamus and pituitary and adrenal gland\n* mobility restriction\n* tetraplegia\n* use of obesity pharmacotherapy\n* malignant disease and chemotherapy\n* pregnancy","20 Years",{"count":372,"type":22},120,[25],"This study aims to evaluate the impact of public health interventions on changes in healthy lifestyle habits over time and their subsequent effects on health outcomes. The investigators hypothesize that exposing at-risk populations to structured physical activity programs, education on healthy nutrition, promotion of the Mediterranean diet, and workshops focused on strengthening psychological resilience will lead to improvements in anthropometric, oxidative, metabolic, and psychological parameters. Anthropometric and laboratory measures will be collected at multiple time points throughout the study. The longitudinal follow-up will span 12 months. It is anticipated that sustained adherence to healthy lifestyle behaviors will result in positive lifestyle changes and enhanced health-related quality of life.",[376,377,378,379,29,380,381,382,383,384,385],"Metabolic Syndrome","Inactivity\u002FLow Levels of Exercise","Unhealthy Diet","Unhealthy Alcohol Use","Stress","Sleep Disorder","Obesity & Overweight","Anxiety","Depressed Mood","Emotional Eating Behaviour",[387,388,389,390,380,391,392,393],"Habits","Lifestlye","Nutrition","Phisical activity","Metabolic syndrome","Mental health","Sleep","2026-02-09",{"date":396,"type":34},"2026-02-12",{"date":398,"type":22},"2026-09-01",{"date":400,"type":22},"2027-12-31",{"name":402,"class":41},"University of Zadar",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":42},"100499994","take-a-break---rural-100499994","NCT05790486","Take A Break - Rural","Using Rural Community Paramedicine to Engage Lower-Motivated Smokers: Spreading an Effective mHealth-Assisted Intervention to Motivate Cessation","TABR","Inclusion Criteria:\n\n* Current Smoker\n* at least 18 years old\n* speaks English\n* Able to receive texts and read text (literate)\n* Have a text-enabled phone or receive one from the study team\n* Not yet ready to quit smoking\n\nExclusion Criteria:\n\n* actively quitting smoking\n* preparing to quit smoking within 30 days\n* prisoners\n* FDA- defined NRT contraindications\n* unable or unwilling to provide informed consent",{"count":231,"type":22},[25],"The study team proposes a multi-level trial to test 1) novel implementation programs in rural counties designed to increase access to 2) recent advances in tobacco control services for people who are not-yet-ready-to-quit smoking. In this field, most trials have focused only on those already ready-to-quit. Thus, the proposed trial addresses an important knowledge gap critical to advance tobacco control in rural areas.",[136,29,108],[416,417,418,419,420,421],"smoking rates","public health tobacco control services","smoking cessation service","Rural Health","Implementation Science","Community Paramedicine",{"date":423,"type":34},"2026-02-11",{"date":425,"type":34},"2023-07-11",{"date":268,"type":22},{"name":428,"class":41},"Wake Forest University Health Sciences",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":436,"targetDuration":437,"studyType":438,"phases":4,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":451,"locationsCount":42},"100617759","smoking-cessation-before-bronchoscopy-or-ct-guided-puncture-100617759","NCT07322796","Smoking Cessation Before Bronchoscopy or CT-guided Puncture","Smoking Cessation Before Intervention in Patients With Pulmonary Nodules Requiring Further Diagnosis","Inclusion Criteria:\n\n* The patient is an active smoker by the time of the initial presentation in our pneumological outpatient clinic for the clarification of a suspicious nodule\n\nExclusion Criteria:\n\n* Current or past medically relevant illness or treatment that could affect the evaluability of the study.\n* Expected lack of willingness to actively participate in study-related measures.",{"count":7,"type":22},"3 Months","OBSERVATIONAL","Nicotine is the most common preventable cause of death and is responsible for over seven million deaths worldwide. If current trends continue, tobacco will kill more than eight million people worldwide every year by 2030. Smoking tobacco products is the most important risk factor for the development of lung cancer. Passive smoking is also a major cause of lung cancer. Since July 2024, smokers and former smokers have been able to receive a low-radiation CT scan under certain conditions to detect lung cancer at an early stage. It is therefore to be expected that the number of diagnoses of pulmonary lesions or nodules will increase in the near future. The risk of developing and dying from tobacco-related diseases is reduced once nicotine cessation begins. Screening all patients for tobacco use, e-cigarette use, and providing behavioral counseling and pharmacotherapy to quit smoking are among the most valuable preventive services we can offer in healthcare.\n\nNicotine dependence can be estimated using the so-called Fagerström test. An additional evaluation of nicotine behavior can be carried out by testing cotinine in urine, a method that is used, for example, in the listing for lung transplantation. Cotinine is a degradation product of nicotine that can be detected in the urine of smokers and passive smokers. Cotinine levels in urine depend on the frequency and quantity of nicotine consumption. The half-life of cotinine is 16 to 22 hours, which means that half of the cotinine is excreted from the body after this time. Another marker that can be used as a measure of tobacco consumption is carboxyhaemoglobin (COHb). This is hemoglobin with carbon monoxide at the binding site for oxygen. The reference range for carboxyhaemoglobin is 0.4 - 1.6 %. In smokers, values of 3-10 % are still considered normal.\n\nIn our department, the smoking status of patients is assessed upon first contact. Support options for smoking cessation are offered and, upon request, initiated. Previous studies have shown that smoking is a risk factor for complications after thoracic surgical procedures and that patients who underwent thoracic surgery quit smoking almost twice as often compared to patients who did not undergo surgery. However, to the best of our knowledge, there is currently no study regarding smoking cessation before intervention in patients with nodules needing clarification (bronchoscopy or CT-guided puncture).\n\nTherefore, the aim of the study is to support and monitor smoking cessation before intervention in patients with nodules needing further diagnosis (bronchoscopy or CT-guided puncture).",[441,29],"Pulmonary Nodule, Solitary",[206,443,444],"smoking cessation","pulmonary nodules","2026-01-26",{"date":447,"type":34},"2026-01-28",{"date":449,"type":34},"2026-01-01",{"date":400,"type":22},{"name":452,"class":41},"RWTH Aachen University",{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":460,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100617818","a-study-to-assess-nicotine-uptake-from-electronic-nicotine-delivery-systems-100617818","NCT07323563","A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems","A Randomized, Crossover, Confinement Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Products","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n* Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n* Positive urine cotinine test at Screening.\n* Smokes combustible, filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n* Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n* Participants must meet one (a or b) of the following tobacco use conditions:\n\n  1. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of the Principal Investigator (PI).\n  2. Dual user of cigarettes and ENDS who self-reports:\n\n  i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence more than 30 days prior to Screening due to illness, quit attempt, or clinical study participation will be allowed at the discretion of the PI and ii. Using a nicotine-containing ENDS (cartridge or tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco and modern oral nicotine products) on no more than 1 day per week will not be excluded from study participation.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n* Willing to use only UB cigarette and assigned test ENDS IPs during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n* Females must be willing to use a form of contraception acceptable to an Investigator, including abstinence from heterosexual intercourse, from the time of signing informed consent until EOS. Examples of acceptable means of birth control include, but are not limited to:\n\n  1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n  2. Physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n  3. Non-hormone-releasing intrauterine devices (IUDs) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n  4. Vasectomized partner;\n  5. Post-menopausal and not on hormone replacement therapy; or\n  6. Sexual abstinence, defined as refraining from intercourse, when this is in line with the preferred and usual lifestyle of the participant.\n* Males must use an acceptable method of birth control from Day 1 Check-in until EOS, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for 5 minutes at Screening and at Check-in Day 1.\n* Weight of ≤ 110 pounds (≤ 50.0 kg) and body mass index of \\> 40.0 kg\u002Fm2 at Screening.\n* Hemoglobin level is \\\u003C 12.5 for females or \\\u003C 13.0 for males g\u002FdL at Screening.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco- or nicotinecontaining products other than cigarettes or ENDS within the last 6 months prior to Screening.\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), glucagon-like peptide-1 (GLP-1) agonists (e.g., Wegovy®, Mounjaro®, Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n* History or presence of bleeding or clotting disorders.\n* Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n* Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and Check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n\n• Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and Check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n\n* Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n* Females who have a positive pregnancy test at Screening or Check-in on Day 1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n* Has positive urine drug screen or alcohol test (urine or breath) at Screening or at Checkin to the Assessment Phase (Day 1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at Check-in (Day 1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an Investigator.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n* Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by the PI, or has a positive alcohol test at Screening or Checkin on Day 1.\n* Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n* Individuals or their family members who have ongoing litigation with tobacco company(ies).\n* Determined by the PI to be inappropriate for this study.",{"count":54,"type":22},[25],"This will be an open-label, randomized, single-site, 8-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters and overall product liking (OPL) following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult combustible cigarette smokers and smokers who also use ENDS products.",[136,29,137,138],"2025-12-22",{"date":466,"type":34},"2026-01-07",{"date":468,"type":22},"2026-03-15",{"date":470,"type":22},"2026-08-31",{"name":148,"class":149},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":479,"targetDuration":4,"studyType":23,"phases":481,"briefSummary":482,"conditions":483,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":4},"100617814","abuse-liability-for-eight-electronic-nicotine-products-100617814","NCT07323511","Abuse Liability for Eight Electronic Nicotine Products","An Open-Label, Randomized, 8-way Crossover Study to Assess Elements of Abuse Liability of Electronic Nicotine Delivery System Products in Adult Smokers","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy male or female, 21 to 60 years of age, inclusive, at the time of consent.\n* Expired breath carbon monoxide level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n* Positive (≥200 ng\u002Fml) urine cotinine test at Screening.\n* Smokes only combustible filtered, menthol or non-menthol cigarettes, 83 mm to 100 mm in length.\n* Agrees to smoke same UB cigarette throughout the study period. UB cigarette is defined as the cigarette brand style currently smoked most frequently by the participant.\n* Participants must meet one (a or b) of the following tobacco use conditions:\n\n  1. Smokes at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (more than 30 days prior to Screening), or clinical study participation (more than 30 days prior to Screening) will be allowed at the discretion of the Principal Investigator (PI).\n  2. Dual user of cigarettes and ENDS who self-reports:\n\n  i. Smoking at least 10 cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening Visit. Brief periods of abstinence more than 30 days prior to screening due to illness, quit attempt or clinical study participation will be allowed at the discretion of the PI and ii. Using a nicotine-containing ENDS (cartridge or a tank system). NOTE: Cigarette smokers or ENDS users who also use other tobacco- or nicotine-containing products (e.g., smokeless tobacco, and modern oral nicotine products) on no more than one day per week will not be excluded from study participation.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes.\"\n* Willing to use only UB cigarette, ENDS IPs, and nicotine gum during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to each test session.\n* Females must be willing to use a form of contraception acceptable to the PI from the time of signing informed consent until End-of-Study.\n* Males must use an acceptable method of birth control from Day 1 \"check-in\" until the end of the study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to in-clinic confinement of 10 days and 9 nights.\n\nExclusion Criteria:\n\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening and at check-in Day 1.\n* Weight of ≤ 110 pounds at Screening.\n* Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C13.0 g\u002FdL for males at Screening.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Must not be a current regular user (i.e., \\> 5 times per month) of any tobacco products other than cigarettes or ENDS within the last 6 months prior to screening.\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Wegovy®, Mounjaro®, and Ozempic®), or lobelia extract within ≤ 30 days prior to the signing of informed consent.\n* History or presence of bleeding or clotting disorders.\n* Use of daily aspirin (≥ 325 mg) or other daily anticoagulants.\n* Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed consent and between Screening and check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a whole blood donation for at least 7 days following study completion.\n\n• Plasma donation within ≤ 7 days prior to the signing of informed consent and between Screening and check-in Day 1.\n\nNOTE: Participants will be advised against scheduling a plasma donation for at least 7 days following study completion.\n\n* Participation in another clinical trial within ≤ 30 days prior to the signing of informed consent. The 30-day window for each participant will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.\n* Females who have a positive pregnancy test at Screening or check-in on Day 1, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.\n* A positive drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening or Day 1.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or a previous quit attempt within ≤ 30 days prior to the signing of the ICF.\n* Has a significant history of alcoholism or drug abuse within 24 months prior to Screening, as determined by the PI, or has a positive alcohol test at Screening or check-in on Day 1.\n* Employed by a tobacco or nicotine company, the study site, or handles tobacco- or nicotine-containing products as part of their job.\n* Individuals or their family members that have ongoing litigation with tobacco company(ies).\n* Determined by the PI to be inappropriate for this study.",{"count":480,"type":22},70,[25],"This will be a randomized, open-label, 8-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]), and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products (IPs) in a confinement setting by generally healthy adult smokers of combustible cigarettes and dual users of cigarettes and ENDS products.",[136,29,137,138],{"date":466,"type":34},{"date":486,"type":22},"2026-02-15",{"date":488,"type":22},"2026-09-15",{"name":148,"class":149},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":506,"locationsCount":42},"100603153","abuse-liability-for-five-modern-oral-nicotine-products-100603153","NCT07132814","Abuse Liability for Five Modern Oral Nicotine Products","An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Five Modern Oral Nicotine Products","Inclusion Criteria:\n\n1. Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco.\n4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.\n5. Smokers who also use ST products (e.g., moist snuff, snus, modern oral), and have used ST within 30 days prior to screening, will be enrolled.\n6. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening.\n8. Positive urine cotinine test (e.g., \\>200 ng\u002FmL) via dipstick at Screening.\n9. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" .\n10. Willing to use the UB cigarette, Study IPs, and Nicorette® nicotine gum (Arm 2 only) during the study period.\n11. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n12. Females must be willing to use a form of contraception acceptable to an investigator from the time of signing the ICF until End-of-Study.\n\n    Examples of acceptable means of birth control are, but not limited to:\n    1. Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral oophorectomy, bilateral salpingectomy);\n    2. physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with spermicide;\n    3. non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs (e.g., Mirena or Kyleena);\n    4. vasectomized partner; or\n    5. post-menopausal and not on hormone replacement therapy.\n13. Agrees to an in-clinic confinement of five days (four nights).\n\nExclusion Criteria:\n\n1. Allergic to or cannot tolerate mint or wintergreen flavoring agents.\n2. Individuals or their family members that have ongoing litigation with tobacco company(ies).\n3. Have used electronic nicotine delivery system (e.g., Vuse Alto, JUUL) or tobacco heating device (e.g., iQOS) within the last 30 days prior to screening.\n4. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.\n5. History, presence of, or clinical laboratory test results indicating diabetes.\n6. Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at an investigator discretion.\n7. History or presence of bleeding or clotting disorders.\n8. Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n9. Systolic blood pressure of \\> 160 mmHg or a diastolic blood pressure of \\> 95 mmHg, measured after being seated for five minutes at Screening or at check-in Day -1.\n10. Weight of ≤ 50.0 kg at screening or at check-in.\n11. Hemoglobin level is \\\u003C 12.5 g\u002FdL for females or \\\u003C 13.0 g\u002FdL for males at Screening.\n12. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n13. Has positive urine drug screen (UDS) or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day -1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of an investigator.\n14. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n15. Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to signing the informed consent.\n16. Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n17. Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n18. Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n19. Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day -1.\n20. Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day -1.\n21. Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n22. Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n23. Drinks more than 21 servings of alcoholic beverages per week.\n24. Determined by an investigator to be inappropriate for this study.",{"count":54,"type":22},[25],"This is a two-site, open-label, randomized, 4-way (2 arm) cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]) during and following ad libitum use of the study investigational products (IPs) by generally healthy smokers",[136,29,137,138],{"date":502,"type":34},"2025-12-30",{"date":504,"type":34},"2025-12-15",{"date":470,"type":22},{"name":148,"class":149},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":131,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":4},"100613484","abuse-liability-for-four-heated-tobacco-product-htp-consumables-and-two-htp-devices-100613484","NCT07267195","Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices","An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Four Heated Tobacco Product (HTP) Consumables and Two HTP Devices","Inclusion Criteria:\n\n* Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.\n* Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.\n* Smokes combustible, filtered, non-menthol (Arm 1 only) or menthol cigarettes (Arm 2 only), 83 mm to 100 mm in length as primary source of tobacco. Smokers who also use other tobacco products (e.g., ENDS, smokeless tobacco, HTPs) will not be excluded from study participation,\n* Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the PI.\n* Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is defined as the reported cigarette brand and style currently smoked most frequently by the participant.\n* Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at Screening and at check-in (Day -1).\n* Positive urine cotinine test (e.g., \\>200 ng\u002FmL) via dipstick at Screening.\n* Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1 (\"How soon after you wake up do you smoke your first cigarette?\") is either \"Within 5 minutes\" or \"6-30 minutes\" (Heatherton et al., 1991).\n* Willing to use the UB cigarette, Study IPs, and Nicorette® nicotine gum during the study period.\n* Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the start of each of four Test Sessions.\n* Females must be willing to use a form of contraception acceptable to the PI from the time of signing the ICF until End-of-Study.\n* Examples of acceptable means of birth control are, but not limited to:\n\n  * Surgical sterilization (hysterectomy, bilateral tubal ligation\u002Focclusion, bilateral\n  * oophorectomy, bilateral salpingectomy);\n  * physical barrier method (e.g., condom, diaphragm\u002Fsponge\u002Fcervical cap) with\n  * spermicide;\n  * non-hormone releasing intrauterine devices (IUD) or hormone-releasing IUDs\n  * (e.g., Mirena or Kyleena);\n  * vasectomized partner; or\n  * post-menopausal and not on hormone replacement therapy\n  * abstinence.\n* Males must use an acceptable method of birth control from Day -1 \"check-in\" until the End-of-Study, unless they have had a vasectomy or are abstinent from heterosexual intercourse, or their female partner is not able to bear children.\n* Agrees to an in-clinic confinement of 10 days (9 nights).\n* BMI within 18.0 to 40.0 kg\u002Fm2, inclusive (minimum weight of at least 50.0 kg at Screening).\n\nExclusion Criteria:\n\n* Individuals or their family members that have ongoing litigation with tobacco company(ies).\n* Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.\n* History, presence of, or clinical laboratory test results indicating diabetes.\n* Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion.\n* History or presence of bleeding or clotting disorders.\n* Any history of cancer, except for primary cancers of skin such as localized basal cell\u002Fsquamous cell carcinoma that has been surgically and\u002For cryogenically removed.\n* Systolic BP of \\> 160 mmHg or a diastolic BP of \\> 95 mmHg, measured after being seated for 5 minutes at Screening or at check-in Day -1.\n* Weight of \\> 50.0 kg at Screening.\n* Hemoglobin level is \\> 12.5 g\u002FdL for females or \\> 13.0 g\u002FdL for males at Screening.\n* Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.\n* Has positive urine drug screen or alcohol test (urine or breath) at Screening or at Check-in to the Assessment Phase (Day -1), with the exception of positive results for tetrahydrocannabinol (THC). If positive for THC at check-in (Day -1), a cannabis intoxication evaluation will be performed, and inclusion will be at the discretion of the PI.\n* Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus (HCV).\n* Use of any medication or substance that aids in smoking cessation, including but not limited to any NRT (e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), GLP-1 agonists (e.g., Mounjaro®, Ozempic®, Wegovy®), or lobelia extract within (≤) 30 days prior to signing the informed consent.\n* Postpones a decision to quit using tobacco- or nicotine-containing products in order to participate in this study or self-reports a previous quit attempt within (≤) 30 days prior to signing the informed consent.\n* Any use of daily aspirin (≥ 325 mg) or any use of other anticoagulants.\n* Individuals ≥ 35 years of age currently using systemic, testosterone, estrogen-containing contraception or hormone replacement therapy.\n* Whole blood donation or lost blood or blood products in excess of 500 mL within 8 weeks (≤ 56 days) prior to signing the informed consent and between Screening and check-in Day -1.\n* Plasma donation within (≤) 7 days prior to signing the informed consent and between Screening and check-in Day -1.\n* Employed by a tobacco or nicotine company, the study site, or handles raw, unpackaged tobacco- or nicotine-containing products as part of their job.\n* Has used an investigational drug, device, biologic, or tobacco\u002Fnicotine product in a previous clinical study within 30 days or 5 times the half-life of the product (whichever is longer) prior to Screening.\n* Drinks more than 21 servings of alcoholic beverages per week.\n* Determined by the PI to be inappropriate for this study.",{"count":54,"type":22},[25],"This is a single-site, open-label, randomized, 8-way crossover study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics \\[PD\\]) and plasma nicotine uptake (pharmacokinetics \\[PK\\]), during and following ad libitum use of the study investigational products (IPs) by generally healthy adult smokers.",[136,29,137,138],"2025-12-08",{"date":520,"type":34},"2025-12-16",{"date":522,"type":22},"2026-01",{"date":268,"type":22},{"name":148,"class":149},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":17,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":539,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":560},"100569396","a-study-evaluating-the-use-of-an-indoor-air-quality-monitor-to-promote-a-smoke-free-home-100569396","NCT06693700","A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home","Freedom to Breathe: Pilot Study Towards Achieving Environmental Justice for Cancer Patients and Their Families","Inclusion Criteria:\n\n* Adult (aged \\>18 years) MSK patients as per the EHR\n* Has been referred and enrolled in the MSK TTP and completed the initial counseling session as per the TTP clinical database\n* Reports current (within the past 30 days) tobacco use (i.e., cigarettes and\u002For any other tobacco products) as per the TTP Intake form\n* Must be English-speaking in the EHR\n* Must be reachable by phone as per self-report\n* Must have Wi-Fi available at home as per self-report\n\nExclusion Criteria:\n\n* Patient reports that no smoking is allowed, by them or anyone else, in the home as per the TTP intake form and\u002For per self-report",{"count":533,"type":22},10,[25],"The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.",[136,108,537,538,29,329,330,165,137,138],"Smoking Reduction","Smoking Habit",[206,443,540,541,542,543,544,545,546,547,548,549,550,551],"smoking reduction","smoking habit","smoking behaviors","smoking, tobacco","smoking, cigarette","smoking (tobacco) addiction","tobacco use","tobacco smoking","air quality","indoor air quality monitoring devices","24-260","Memorial Sloan Kettering Cancer Center","2025-10-21",{"date":554,"type":34},"2025-10-22",{"date":556,"type":34},"2024-11-14",{"date":558,"type":22},"2027-11-14",{"name":551,"class":41},8,{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":438,"phases":4,"briefSummary":572,"conditions":573,"keywords":576,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":42},"100499566","health-opportunities-and-promoters-of-equitable-screening-for-lung-cancer-100499566","NCT05784922","Health Opportunities and Promoters of Equitable Screening for Lung Cancer","Health Opportunities and Promoters of Equitable Screening for Lung Cancer (HOPES for Lung Cancer)","HOPES","Inclusion Criteria:\n\n* Must be 50-80 years old\n* Are a current or former smoker (quit within 15 years, or a cumulative smoking status of \\> 20 pack-years)\n* Not currently enrolled in Lung Cancer Screening\n* Must speak English or Spanish\n\nExclusion Criteria:\n\n* Has a clinical cognitive inability to provide informed consent for participation in the study or complete a brief survey\n* Currently diagnosed with lung cancer\n* Currently enrolled in lung cancer screening\n* Have participated in the focus groups discussions from Aim 1","80 Years",{"count":571,"type":22},2000,"The goal of this clinical trial is to promote lung cancer screening (LCS) uptake among Hispanic current and former smokers. The main questions it aims to answer are:\n\n* What barriers do current and former Hispanic smokers face in the identification and documentation of their smoking status?\n* How can digital delivery of an educational video promote LCS uptake among current and former Hispanic smokers?\n\nParticipants will receive an educational video about lung cancer screening and complete brief, self-reported surveys afterwards.",[574,29,575],"Lung Cancer","Diagnosis",[577,578,579,580,581,582,583],"lung cancer screening","Hispanic outreach","educational intervention","digital health","smoking documentation","smoking history","health equity","2025-10-10",{"date":586,"type":34},"2025-10-14",{"date":588,"type":34},"2023-02-03",{"date":590,"type":22},"2028-01-31",{"name":592,"class":41},"Massachusetts General Hospital",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":42},"100478738","phase-1-overcoming-nicotine-dependence-to-enable-quitting-100478738","NCT05513872","Overcoming Nicotine Dependence to Enable Quitting","A Mechanistic Test of Treatment Strategies to Foster Practice Quitting","ON-DEQ","Inclusion Criteria:\n\nEligible participants will be males and females who:\n\n1. are 18 years or older\n2. report current daily cigarette smoking (≥ 5 cigarettes per day)\n3. are not planning to quit in the next 30 days\n4. are not currently engaged in smoking cessation treatment\n5. are motivated to quit or engage in a non-cessation goal (i.e., reduce smoking, learn more about treatment options, and\u002F or try out skills to change smoking) in the next 6 months\n6. are English speaking\n7. reside in the continental United States\n8. have access to a smartphone that can be used to complete study procedures\n\nExclusion Criteria:\n\nParticipants will be excluded for daily vaping\u002F electronic cigarettes use (i.e., use for ≥ 25 days within past 30 days) and any FDA contraindications for NRT use if they:\n\n1. are pregnant\u002Fbreastfeeding\n2. had recent cardiovascular trauma such as myocardial infarction\n3. had a stroke within the past 3 months",{"count":602,"type":22},780,[304,105],"Tobacco use disorder is a chronic, relapsing health condition that necessitates a chronic care approach. However, traditional smoking cessation treatment programs allocate nearly all their resources only to those smokers who are willing to set a quit date. This is problematic because few smokers are ready to set a quit date at any given time, and a smoker's stated intention to quit can change rapidly.\n\nOne novel potential treatment strategy is to foster practice quitting (PQ), defined as attempting to not smoke for a few hours or days, without pressure or expectation to permanently quit. Although a growing body of evidence supports the role of practice quitting in fostering permanent quit attempts and cessation, there is a significant knowledge gap regarding which treatment strategies should be used to engage smokers in practice quitting. The proposed study will test the role of PQ counseling vs. Motivational Interviewing (MI) counseling, and NRT sampling (four-week supply of nicotine lozenges and patches) vs. none.",[137,108,29,283,606],"Nicotine Withdrawal",[608,443,609,610,611],"tobacco","nicotine dependence","nicotine replacement therapy","behavioral treatment","2025-08-13",{"date":614,"type":34},"2025-08-17",{"date":616,"type":34},"2023-03-24",{"date":618,"type":22},"2027-08-30",{"name":620,"class":41},"Rush University Medical Center",{"id":622,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":624,"briefSummary":26,"conditions":625,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":630,"leadSponsor":631,"locationsCount":42},"100544806",{"count":21,"type":22},[25],[28,29],"2025-07-22",{"date":628,"type":34},"2025-07-25",{"date":36,"type":34},{"date":38,"type":22},{"name":40,"class":41},{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":158,"maxAge":51,"enrollmentInfo":639,"targetDuration":4,"studyType":438,"phases":4,"briefSummary":641,"conditions":642,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":648,"leadSponsor":650,"locationsCount":42},"100596320","impact-of-smoking-on-physical-activity-level-in-young-adults-100596320","NCT07043920","Impact of Smoking on Physical Activity Level in Young Adults","The Association Between Daily Physical Activity Level and Nicotine Dependence in University Students: A Cross-Sectional Study","Inclusion Criteria:\n\n* Aged ≥18 years\n* Studying in a health-related university program\n* Healthy individuals (no known chronic disease)\n* Voluntarily agreeing to participate\n\nExclusion Criteria:\n\n* History of cardiovascular disease, cancer, or severe respiratory illness\n* Pregnancy\n* Age under 18",{"count":640,"type":22},164,"This study will aim to examine the relationship between the daily physical activity level and nicotine dependence severity in university students. By identifying whether a higher physical activity level is associated with lower levels of smoking, the findings will help inform interventions to support healthier lifestyles in young adults.",[29,643],"Physical Inactivity","2025-07-01",{"date":646,"type":34},"2025-07-02",{"date":644,"type":34},{"date":649,"type":22},"2026-07-01",{"name":651,"class":41},"Saglik Bilimleri Universitesi"]